ACLY (ATP-citrate lyase) is a key metabolic enzyme that catalyzes the conversion of citrate and coenzyme A into acetyl-CoA and oxaloacetate, linking carbohydrate metabolism to lipid synthesis. Acetyl-CoA serves as a critical precursor for fatty acid and cholesterol biosynthesis, making ACLY essential in cellular energy homeostasis and proliferation. Dysregulation of ACLY is implicated in metabolic disorders, cancer, and cardiovascular diseases, as its overexpression enhances lipogenesis in tumors and contributes to hyperlipidemia.
ACLY antibodies are immunological tools designed to detect, quantify, or inhibit ACLY protein in research and diagnostic contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study ACLY expression patterns in tissues or cell lines, particularly in cancer metabolism studies. Specific antibodies may target distinct epitopes, including phosphorylated forms (e.g., at Ser455), to assess activation states regulated by signaling pathways like AKT.
Therapeutic interest in ACLY has surged due to its role as a druggable target; inhibitors like bempedoic acid (ETC-1002) are approved for lowering LDL cholesterol. ACLY antibodies thus also support drug development by validating target engagement or monitoring biomarker responses. Their applications span basic research on metabolic reprogramming, clinical biomarker discovery, and preclinical evaluation of metabolic therapies.